EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Salvage Therapy with Rezafungin for Candida parapsilosis Spondylodiscitis: A Case Report from Expanded Access Program

Giulio Viceconte, Antonio Riccardo Buonomo iD, Nunzia Esposito iD, Letizia Cattaneo, Teresa Somma, Maria Michela Scirocco, Ciro Gabriele Mainolfi, Ivan Gentile iD

Microorganisms · 30.04.2024 · 12 (5) · 903

DOI: 10.3390/microorganisms12050903 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Microorganisms, online erschienen am 30.04.2024. Verfasst von Giulio Viceconte und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples "Federico II", 80131 Naples, Italy. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Candida spp. spondylodiscitis is a rare condition for which treatment options are often limited. A further obstacle is the duration of therapy, which should be administered for up to twelve months. In view of the long duration of therapy, azoles are, so far, the only oral treatment strategy that can be given as home therapy. In the case of resistance or reduced susceptibility to azoles, there are not enough comfortable treatment opportunities with adequate bone penetration and limited toxicity. We report the first case of the successful use of rezafungin for spondylodiscitis due to Candida parapsilosis with reduced susceptibility to azoles. A 68-year-old patient, affected by paraplegia and short bowel syndrome, was diagnosed with Candida parapsilosis spondylodiscitis, confirmed with a culture on vertebral biopsy after an 18-FDG PET/CT scan. He received 200 mg of rezafungin weekly for 26 weeks, after 10 weeks of previous antifungal treatment that was not well tolerated with voriconazole plus liposomal amphotericin B. He had a full clinical, radiologic, and biochemical response to the therapy with rezafungin, with no adverse effects. Rezafungin can be a promising therapy for Candida osteomyelitis, especially when first line therapies are ineffective, poorly tolerated, or contraindicated.

Schlagwörter

Stichwörter der Autor:innen

Candidaosteomyelitisrezafunginspondylodiscitis

Autor:innen und Institutionen

  • Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples "Federico II", 80131 Naples, Italy.
  • Department of Neurological Sciences, Division of Neurosurgery, University of Naples "Federico II", 80131 Naples, Italy.
  • Department of Advanced Biomedical Sciences, University of Naples "Federico II", 80131 Naples, Italy.

ORCID-Profile: Antonio Riccardo Buonomo, Nunzia Esposito, Ivan Gentile

Zitieren

APA

Viceconte, G., Buonomo, A. R., Esposito, N., Cattaneo, L., Somma, T., Scirocco, M. M., Mainolfi, C. G., & Gentile, I. (2024). Salvage Therapy with Rezafungin for Candida parapsilosis Spondylodiscitis: A Case Report from Expanded Access Program. Microorganisms, 12(5), 903. https://doi.org/10.3390/microorganisms12050903

Vancouver

Viceconte G, Buonomo AR, Esposito N, Cattaneo L, Somma T, Scirocco MM, et al. Salvage Therapy with Rezafungin for Candida parapsilosis Spondylodiscitis: A Case Report from Expanded Access Program. Microorganisms. 2024;12(5):903. doi:10.3390/microorganisms12050903

BibTeX
@article{Viceconte2024,
  author = {Viceconte, Giulio and Buonomo, Antonio Riccardo and Esposito, Nunzia and Cattaneo, Letizia and Somma, Teresa and Scirocco, Maria Michela and Mainolfi, Ciro Gabriele and Gentile, Ivan},
  title = {Salvage Therapy with Rezafungin for Candida parapsilosis Spondylodiscitis: A Case Report from Expanded Access Program},
  journal = {Microorganisms},
  year = {2024},
  volume = {12},
  number = {5},
  pages = {903},
  doi = {10.3390/microorganisms12050903}
}
Kostenlos starten →